Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0437)
Name
DNA (cytosine-5)-methyltransferase 1
Drug Type
Protein
Full List of Ferroptosis Target Related to This Drug
Nuclear receptor coactivator 4 (NCOA4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Ischemia/reperfusion injury ICD-11: DB98
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model CHO-S/H9C2 cells Normal Cricetulus griseus CVCL_A0TS
In Vivo Model
Fifty specific pathogen-free male SpragueDawley rats (weighing 210-240 g) were purchased from Beijing Huakang Biotechnology Co., Ltd (Beijing, China). The DS model was established by injecting 1% streptozotocin into the tail vein at 60 mg/kg dose. After 3 days, if the fasting blood glucose level was higher than 16.7 mmol/L, the DS model was successfully built. The NS and the I/R group were given 0.9% sodium chloride injection. Thereafter, the general conditions for normal and DM rats are showed in Table Table2.2. After 8 weeks, all the rats were intraperitoneally injected with 1.5% sodium pentobarbital at a dose of 0.005 mL/g. They were given electrocardiogram (ECG) monitoring management.

    Click to Show/Hide
Response regulation Inhibition of DNA (cytosine-5)-methyltransferase 1 (DNMT-1) could reduce ferroptosis during diabetes myocardial ischemia/reperfusion injury and the NCOA4-mediated ferritinophagy may participate in the process.
References
Ref 1 Inhibition of DNMT-1 alleviates ferroptosis through NCOA4 mediated ferritinophagy during diabetes myocardial ischemia/reperfusion injury. Cell Death Discov. 2021 Sep 29;7(1):267. doi: 10.1038/s41420-021-00656-0.